NYSE-listed global leader in Life Sciences, diagnostics and applied chemical markets Agilent Technologies has established a Biopharma Experience Centre in Hyderabad to support the drug development journey of its customers.
End-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis and lab informatics that will allow its customers to simulate real lab environments are available. The companies can test for quality and compliance and co-create market-ready solutions, Industries and IT Minister D.Sridhar Babu’s office said after he inaugurated the facility on Tuesday.
Launch of the facility is a significant milestone in strengthening Telangana’s position as a global leader in Life Sciences and a valuable addition to expanding innovation-driven ecosystem, the Minister said.
Rounded ecosystem
Hyderabad has emerged as a complete healthcare and life sciences ecosystem, from contributing to drug discovery and clinical trials to playing host to world-class hospitals and affordable, high-quality patient care. “We are proud to host eight of the top ten global pharma companies, five of India’s leading healthcare chains and over 230 U.S Food and Drug Administration (U.S FDA)-approved manufacturing facilities,” Mr.Sridhar Babu said.
Telangana contributes nearly one-third of India’s pharmaceutical production and 40% of bulk drug exports from the country. “With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system,” he said. Agilent’s new facility is poised to serve as a hub for innovation and collaboration, supporting development of biologics, biosimilars and precision medicine, the Minister’s office said.
“India is a strategic growth market for Agilent,” Agilent president and CEO Padraig McDonnell said.
Serving as foundation for the new centre is Hyderabad’s mature and future-focused life sciences ecosystem that thrives on deep industry expertise, strong research and development capabilities and a supportive policy environment. With its legacy in generics and a focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation.
Without mentioning either the investment or hiring plans, Agilent said its capital investment in the facility is part of a broader three-to-five-year India growth strategy. The India Solution Centre in Manesar launched earlier this year further is a reflection of its commitment to enhance presence and capabilities in one of its fastest-growing, high-priority markets globally.
Published – July 30, 2025 02:39 am IST
